RevMedica, Inc. ’s Post

#exosomes are a hot topic in #aesthetics right now. Thank you Victoria Martin for helping us understand what they are and what they do. Though exosomes are important, MANY different #biomolecules are needed to #regenerate and #healskin .… It's amazing how complex and intelligent our bodies are! #advancedmedicine #exosomes #skinhealthexperts

What are Exosomes? 🤷🏻♀️ Exosomes are a type of extracellular vesicle. They are little packages of cargo that bubble off the cells in our body. Still curious? Check out the video for more! Thank you Victoria Martin VP of clinical and regulatory affairs ReyaGel for this insightful video! #ReyaGel #SkinHealing #ExosomeTechnology #AdvancedSkincare #HealthySkin #mtp

Listerine (@listerine) was invented by Dr. Joseph Lawrence who chose to name his work after someone who inspired him. Joseph Lister was an English doctor and surgeon who believed in the concept of using sterilization and antiseptics in the operating room. Because of this practice, more patients survived surgeries and countless infections were prevented. Lawrence took this idea and used it to create a product that could kill germs in your mouth the same way. #Acleanlikenoother #sciencesaves #germkiller #listerine #doctorschangetheworld #funfact #pharmacistfunfact #pharmacy #healthfact #pharmacies #rx #creorx #creorxsolutions #drugstore #healing #healingpowers #medicine #origins #listerine

🧐We welcome you to read "#Artificialintelligence for ophthalmic #drug discovery and development: Capabilities, applications, and challenges" 👥By Siddharth Gandhi & Michael Balas. Read it here #OpenAccess: https://lnkd.in/gZ_X3y2r

Awesome result for the TLX101-CDx team and as well for future patients. Distinguishing between true #progression and treatment induced changes is not straightforward with conventional methods

🚶♀️ Regenity Biosciences secures FDA 510(k) approval for RejuvaKnee implant device RejuvaKnee is a minimally invasive collagen-based implant indicated for reinforcing and repairing soft tissue injuries of the meniscus. Derived from natural bovine collagen, the device promotes host tissue ingrowth and facilitates the repair of damaged meniscal tissue. It promotes a more complete recovery by supporting the regeneration of native meniscal tissue, providing an alternative to cutting or replacing the damaged tissue. Read more online: https://lnkd.in/eACvJk8q 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

Chardan is pleased to have acted as Sole Placement Agent on Eyenovia, Inc.’s Registered Direct Offering. Eyenovia, Inc. is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. The company’s current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi® for mydriasis.  Read more about the transaction here: https://lnkd.in/ex-kH4FE or reach out to info@chardan.com #ChardanTransactions #ophthalmology

Harrow has announced the manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA‑approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. https://bit.ly/3VA7uLS

The U.S. FDA has granted Fast Track designation for Telix’s investigational PET imaging agent, TLX101-CDx (Pixclara™), for the characterisation of progressive or recurrent glioma. There is critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting where conventional MRI – the standard of care – can often be inconclusive. Telix also today announces a unique academic-industrial collaboration with University of California, San Francisco (UCSF) supporting joint development and commercialisation, and PharmaLogic Holdings Corp. as commercial manufacturing and distribution partner for TLX101-CDx, subject to regulatory approval. Read more here: https://bit.ly/49G7aAa

Excellent progress